Evelo Biosciences Inc. (NASDAQ:EVLO) does about 123.75K shares in volume on a normal day but saw 444713 shares change hands in Friday trading. The company now has a market cap of 95.13M USD. Its current market price is $0.82, marking an increase of 1.12% compared to the previous close of $0.81. The 52 week high reached by this stock is $4.36 whilst the lowest price level in 52 weeks is $0.74. The script in recent trading has seen the stock touch a high of $0.8786 and a low of $0.79.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Evelo Biosciences Inc. (EVLO) has a 20-day trading average at $0.9234 and the current price is -81.10% off the 52-week high compared with 11.35% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.2960 and its 200-day simple moving average is $1.9489. If we look at the stock’s price movements over the week, volatility stands at 7.78%, which increases to 10.35% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 34.24 to suggest the stock is neutral.
The consensus objective for the share price is $4.32, suggesting that the stock has a potential upside of 81.02% over the period.
FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 01, 2021 when Chardan Capital Markets upgraded the stock to “Buy” and issued a price target of $12. Jefferies upgraded its price target at $11-$18.
The current price level is -11.75%, -37.55%, and -57.94% away from its SMA20, SMA50, and SMA200 respectively, with the EVLO price moving above the 50-day SMA on February 17. Evelo Biosciences Inc. (EVLO) stock is down -1.36% over the week and -25.09% over the past month. Its price is -48.82% year-to-date and -79.40% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.28 above consensus estimates by $0.05. EVLO’s earnings per share are forecast to grow by 39.80% this year and 28.10% over next year.
To reach the target analysts have set, the stock logically needs to grow 81.02 percent from here.
Outstanding shares total 108.05M with insiders holding 0.13% of the shares and institutional holders owning 85.32% of the company’s common stock. The beta has a value of 1.31. Price to book ratio is 9.16.
According to a U.S. Securities and Exchange Commission filing, Fidelity Growth Company Fund has reduced its position in Evelo Biosciences Inc. (EVLO) to 4,777,470 shares, mirroring a recent drop by -0.68%. Fidelity Growth Company Fund dumped 32754.0 shares of Evelo Biosciences Inc. common stock bringing its total worth to about $4.97 million at the end of recent close, SEC documents show. Fidelity Growth Company Fund isn’t the only investment manager who changed stakes and is followed by CS Invt Fds 2 -, which added 10415.0 shares to end up with 3,610,415 shares worth $3.75 million. DNCA Invest – Beyond Global Leade raise their holdings by 19.20% in the company over the course of the most recent quarter. It now holds a 3.19% position in Evelo Biosciences Inc. thanks to 3.49 million shares amounting to $3.63 million.
